Management of chronic, refractory schizophrenic patients with high-dose loxapine

L. Ereshefsky, S. R. Saklad, T. E. Mings, C. R. Lehmann

    Research output: Contribution to journalArticle

    2 Scopus citations

    Abstract

    The authors suggest that schizophrenic patients unresponsive to other antipsychotic agents should be considered for a trial on loxapine. The loxapine dosage should be slowly titrated upward unless rapid tranquilization is indicated. Use of the liquid form of medication is recommended for initiation of routine loxapine therapy to assure compliance during titration. Loxapine has been reported to cause seizures in overdose, justifying careful screening of patients for high-dose loxapine therapy. Double-blind, placebo-controlled trials are needed to verify the superiority of loxapine over other antipsychotic agents.

    Original languageEnglish (US)
    Pages (from-to)600-603
    Number of pages4
    JournalPsychopharmacology bulletin
    Volume19
    Issue number4
    Publication statusPublished - Jan 1 1983

      Fingerprint

    ASJC Scopus subject areas

    • Psychiatry and Mental health
    • Pharmacology (medical)

    Cite this

    Ereshefsky, L., Saklad, S. R., Mings, T. E., & Lehmann, C. R. (1983). Management of chronic, refractory schizophrenic patients with high-dose loxapine. Psychopharmacology bulletin, 19(4), 600-603.